Iraj Sharifi
Overview
Explore the profile of Iraj Sharifi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
1348
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zarrinkar F, Sharifi I, Oliaee R, Afgar A, Molaakbari E, Bamorovat M, et al.
Parasite Epidemiol Control
. 2025 Feb;
28:e00413.
PMID: 39959455
Antiparasitic resistance represents a serious global public health concern with tremendous economic and safety implications. This study intended to investigate the expression of the two major resistant markers: cystathionine β...
2.
Shafiei-Bafti M, Taghavi-Shirazi M, Sharifi I, Safa F
J Res Med Sci
. 2025 Jan;
29():78.
PMID: 39871873
No abstract available.
3.
Sharifi I, Salarkia E, Dabiri S, Pardakhty A, Sharifi F, Mohamadi N
Exp Parasitol
. 2024 Nov;
267:108859.
PMID: 39505195
The use of conventional drugs is not a satisfactory treatment for the disease. Therefore, there is a crucial need for alternative therapeutic approaches. This study aimed to investigate the potential...
4.
Akhtardanesh B, Sadr S, Khedri J, Bamorovat M, Salarkia E, Sharifi I
Sci Rep
. 2024 Oct;
14(1):25599.
PMID: 39465272
Dogs are the primary reservoirs of Leishmania infantum (L. infantum), but Leishmania tropica (L. tropica) infection is also possible in dogs and can transmitted to humans. The southeast of Iran...
5.
Zarrinkar F, Sharifi I, Salarkia E, Keyhani A, Babaei Z, Khamesipour A, et al.
PLoS One
. 2024 Aug;
19(8):e0307537.
PMID: 39213335
Currently, no safe vaccine against leishmaniasis is available. So far, different control strategies against numerous reservoir hosts and biological vectors have not been environment-friendly and feasible. Hence, employing medicinal components...
6.
Shahsavari S, Sharifi I, Salarkia E, Keyhani A, Sharifi F, Babaei Z
Immunol Res
. 2024 Aug;
72(6):1313-1326.
PMID: 39155331
Conventional therapeutic agents are no longer adequate against leishmaniasis. This complex condition continues to have a high mortality rate and public health impact. The present study aimed to explore an...
7.
Bamorovat M, Sharifi I, Khosravi A, Aflatoonian M, Agha Kuchak Afshari S, Salarkia E, et al.
J Epidemiol Glob Health
. 2024 Mar;
14(1):22-34.
PMID: 38466368
Leishmaniasis is a disease of poverty that imposes a devastating medical, social, and economic burden on over 1 billion people nationwide. To date, no in-depth study to analyze the major...
8.
Seyedi F, Sharifi I, Khosravi A, Molaakbari E, Tavakkoli H, Salarkia E, et al.
Sci Rep
. 2024 Jan;
14(1):2482.
PMID: 38291076
Various drugs have been used for the treatment of leishmaniasis, but they often have adverse effects on the body's organs. In this study, we aimed to explore the effects of...
9.
Bamorovat M, Sharifi I, Shafiei Bafti M, Agha Kuchak Afshari S, Aflatoonian M, Karamoozian A, et al.
J Epidemiol Glob Health
. 2024 Jan;
14(1):142-153.
PMID: 38190050
Introduction: Emerging infectious diseases such as SARS-CoV-2 can cause pandemics and create a critical risk for humans. In a previous pilot study, we reported that the immunological responses induced by ...
10.
Bamorovat M, Sharifi I, Aflatoonian M, Salarkia E, Agha Kuchak Afshari S, Pourkhosravani M, et al.
Sci Total Environ
. 2023 Dec;
913:169684.
PMID: 38160824
Leishmaniasis is a complex disease. Any change in weather conditions affects the humans' social and agricultural expansion and, consequently, the parasite's life cycle in terms of ecology, biodiversity, social stigma,...